PVP BIOLOGICS
PvP Biologics is developing an oral enzyme for the treatment of celiac disease. Our mission is to develop a highly-effective therapeutic product to reduce the burden of living with this disease. Towards this end, we are advancing a product candidate designed to break down the immuno-reactive parts of gluten in the stomach and thereby avoid the painful symptoms and damage done in the small intestine from accidental gluten ingestion.
PVP BIOLOGICS
Industry:
Biotechnology Health Care Pharmaceutical Therapeutics
Founded:
2016-11-01
Address:
San Diego, California, United States
Country:
United States
Website Url:
http://www.pvpbio.com
Total Employee:
11+
Status:
Closed
Total Funding:
35 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF Microsoft Exchange Online Office 365 Mail GoDaddy DNS Google Google Cloud Pound Sterling OpenResty
Similar Organizations
Gene Sciences, Inc.
Gene Sciences Inc. is developing novel DNA targeted therapeutics for the treatment of human genetic diseases.
Kodiak Sciences
Kodiak is designing and developing novel therapies for the treatment of retinal disease.
Milestone Pharmaceuticals
Milestone Pharmaceuticals is a drug development company developing small molecule therapeutics for the treatment of cardiovascular diseases.
Pliant Therapeutics
Pliant Therapeutics focuses on discovering, developing, and commercializing breakthrough treatments for fibrotic diseases.
Qpex Biopharma
Qpex Biopharma develops a pipeline of agents addressing critical needs for the treatment of infectious diseases.
Tzofen Biological Therapeutics
TZOFEN biological therapeutics are developing a novel biological platform for the treatment of various cancer types.
Upstream Bio
Upstream Bio focuses on developing an antibody therapy for the treatment of severe asthma.
Current Employees Featured
Founder
Investors List
Sahsen Ventures
Sahsen Ventures investment in Venture Round - PvP Biologics
Takeda
Takeda investment in Venture Round - PvP Biologics
Official Site Inspections
http://www.pvpbio.com
- Host name: 132.100.252.198.static.reverse.arandomserver.com
- IP address: 198.252.100.132
- Location: Chantilly United States
- Latitude: 38.8879
- Longitude: -77.4448
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20151
More informations about "PvP Biologics"
Leadership โ PvP Biologics
As the faculty director of the IIFH he has led the efforts taking the concept of this organization and building an infrastructure capable of rapidly scaling, initiating cross-disciplinary and multi โฆSee details»
PvP Biologics - Crunchbase Company Profile & Funding
PvP Biologics is developing an oral enzyme for the treatment of celiac disease. Our mission is to develop a highly-effective therapeutic product to reduce the burden of living with this disease. โฆSee details»
PvP Biologics, Inc. | LinkedIn
PvP Biologics, Inc. | 360 followers on LinkedIn. Novel Therapeutics for Celiac Disease | PvP Biologics is developing an oral enzyme for the treatment of celiac disease. Our mission is to โฆSee details»
PvP Biologics, Inc. Overview | SignalHire Company Profile
PvP Biologics, Inc. is a private company that has been in the industry for 7 years. The company currently specializes in the Pharmaceuticals, Pharmaceuticals areas. The position of the โฆSee details»
PvP Biologics Announces Leadership Team - BioSpace
Jan 5, 2017 The technology was invented at the Institute for Protein Design at University of Washington and exclusively in-licensed by PvP Biologics. PvP Biologics has corporate offices โฆSee details»
PvP Biologics, Inc. | Insights
Feb 26, 2020 Takeda Pharmaceutical Co. Ltd. has acquired the private San Diego-based venture PvP Biologics Inc. , following promising early clinical results with the university spin โฆSee details»
Our History โ PvP Biologics
The KumaMax project got its start in 2011 as an undergraduate project at the University of Washington (UW) for the international Genetically Engineered Machine (iGEM) competition. โฆSee details»
PvP Biologics 2025 Company Profile: Valuation, Investors
Information on acquisition, funding, investors, and executives for PvP Biologics. Use the PitchBook Platform to explore the full profile.See details»
PVP Biologics - CoMotion
Jan 1, 2015 PVP Biologics (acquired by Takeda in February, 2020) is developing an oral enzyme for the treatment of celiac disease. Celiac disease is an inflammatory intestinal โฆSee details»
News โ PvP Biologics
Jan 6, 2017 In a unique deal, PvP Biologics skipped venture funding and brought on pharma partner Takeda in a $35 million agreement to advance a therapeutic candidate, called โฆSee details»
Portfolio | Sahsen
Novel therapeutics for Celiac Disease PvP Biologics was spun-out of the University of Washingtonโs Institute for Protein Design in 2016 by lead investigator Ingrid Swanson Pultz โฆSee details»
PvP Biologics Announces Leadership Team - PR Newswire
Jan 5, 2017 /PRNewswire/ -- PvP Biologics today announced the company's leadership team. The company was formed to advance an oral enzyme therapy, called KumaMax, for the...See details»
Pvp Biologics, Inc. (Pvp Biologics, Inc.) - ่ฏ็ฉ็ฎก็บฟ_ไธๅฉ_ไธดๅบ่ฏ้ช_ โฆ
This is a single blind, dose escalating, placebo-controlled, crossover study of gluten-degrading drug PvP001 administered to healthy volunteers (age 18-64 years). Subjects will be โฆSee details»
PVP Biologics | VentureRadar
PvP Biologics is a UW spinoff that is developing an oral enzyme for the treatment of celiac disease which affects an estimated 2.4 million Americans. The technology was invented over โฆSee details»
Takeda and PvP Biologics Announce Development Agreement โฆ
The technology was invented at the Institute for Protein Design at University of Washington and exclusively in-licensed by PvP Biologics. PvP Biologics has corporate offices in San Diego and โฆSee details»
PVP Biologics - Founders and Board of Directors - Tracxn
Mar 23, 2025 PVP Biologics's founders include Justin Siegel, David Baker and 1 other.See details»
PVP Biologics - VentureRadar
PvP Biologics is a UW spinoff that is developing an oral enzyme for the treatment of celiac disease which affects an estimated 2.4 million Americans. The technology was invented over โฆSee details»
PvP Biologics Announces First-in-Human Clinical Trials for a Novel ...
Sep 6, 2018 SAN DIEGO and SEATTLE, September 6, 2018 โ PvP Biologics, Inc. (โPvPโ) today announced the initiation of two first-in-human clinical trials for Kuma062, a product candidate โฆSee details»
PvP Biologics, Inc. - Overview, Competitors, And Employees - Ampliz
PvP Biologics, Inc.`s Overview, Revenue, Employee Size, Location For Free. Find Key Decision Makers Of PvP Biologics, Inc. Email, Phone, LinkedIn Profile.See details»
PvP Biologics
PvP Biologics. 1,036 likes. PvP Biologics is developing an oral enzyme for the treatment of celiac disease aimed at reducing the burden of living with this disease.See details»